SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients

Taking sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) didn’t prevent kidney results for clients hospitalized with COVID-19, according to a secondary analysis of the DARE-19 trial.

Among clients with cardiometabolic threat aspects, those taking dapagliflozin saw a comparable incident for a composite kidney result of intense kidney injury (AKI), kidney replacement treatment, or death (HR 0.74, 95% CI 0.50 -1.07), reported Hiddo Lambers Heerspink, PhD, PharmD, of the University of Groningen in The Netherlands, and associates.

This composite result took place in 8% of the dapagliflozin clients and 10% of the placebo group, the group composed in CJASN, Clinical Journal of the American Society of Nephrology

The threat for this composite kidney result didn’t vary in between standard approximated glomerular filtering rate (eGFR), either:

• <

  Kristen Monaco is a personnel author, concentrating on endocrinology, psychiatry, and nephrology news. Based out of the New York City workplace, she’s operated at the business given that2015

Disclosures

The research study was supported by AstraZeneca Pharmaceuticals.

Heerspink and co-authors different ties to market, consisting of with AstraZeneca.

Tuttle likewise reported numerous ties to market, consisting of with AstraZeneca.